VKTX stock holds after Q2 loss narrows

VKTX stock is holding after a second-quarter 2026 loss of $1.10 a share and $502 million in cash. Traders are also weighing a 2.3% gain since the last earnings report and August 27, 2026 price action.

Viking Therapeutics stock (VKTX) is trading on a narrow Q2 2026 earnings beat, a cash balance of $502 million and an after-hours quote of $33.97 on August 28, 2026. The company said the second-quarter 2026 loss was $1.10 per share, better than the $1.21 consensus loss, while research and development spending rose 92.4% year over year to $115.8 million.

Cash and burn stay central

That mix matters because the June quarter ended with $502 million in cash, cash equivalents and short-term investments, down from $603 million at the end of the first quarter of 2026. Viking also said existing resources should fund operations into 2028, a point that frames the stock around trial spending rather than sales growth.

The same update showed general and administrative expenses climbing 16.8% to $16.8 million. On a market basis, the shares had added 2.3% since the last earnings report, but the stock was still down 3.75% year to date as of August 27, 2026.

Pipeline timing matters

For investors, the next visible swing factor is trial timing rather than product revenue, because Viking still has no approved products and has yet to generate revenue. The Q3 2026 data window now carries more weight than the quarter that just closed.

That makes the comparison simple: a $502 million cash position against a 92.4% surge in R&D spending is the core tension in the story. The stock has also outperformed the S&P 500 over 1 year, with a 27.20% gain versus 19.28% for the index.

VK2735 stays the product

VK2735 remains the lead obesity program and the main reason the company keeps drawing investor attention. The market is watching whether upcoming readouts can justify the spending trajectory and support the cash runway Viking described in its June-quarter update.

Share price and setup

VKTX traded at $33.86 at the August 28, 2026 close and at $33.97 in after-hours trading. The move leaves the shares well above the year-to-date low implied by the 3.75% decline and keeps the focus on the next clinical update.

Fact box

Company: Viking Therapeutics, Inc.
ISIN: US92686J1060
Ticker: VKTX
Exchange: NasdaqCM - Nasdaq Real Time Price
Price (as of August 28, 2026, 6:57 p.m. ET): $33.97 USD
Market cap: $3.83 billion
Sector / Industry: Health Care / Biotechnology
Index membership: Russell 2000

More on VKTX stock

Viking Therapeutics, Inc. is built around VK2735 and other metabolic pipeline assets, with the obesity program now carrying the clearest commercial optionality. The June quarter's $115.8 million in R&D spending shows how expensive that push has become.